Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VR-Care: A Feasibility Study of Virtual Reality to Advance Dementia Care and Quality of Life

NCT07893678 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07893678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
VR-Care: A Feasibility Study of Virtual Reality to Advance Dementia Care and Quality of Life
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 30, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

agitation, agitation aggression in dementia, behavioural and psychological symptoms of dementia, dementia, major neurocognitive disorder

Arms

As registered; 1 arm.

  • Supervised Virtual Reality Intervention ExperimentalSupervised Virtual Reality Sessions

    All enrolled participants will be offered a brief, supervised virtual reality (VR) familiarization or orientation procedure using commercially available VR headset technology and the Rendever platform content library. Completion of tolerated familiarization is required before regular VR intervention sessions may begin. Familiarization will not constitute intervention initiation and will not count as a regular VR session. Participants who tolerate familiarization may be offered up to three regular supervised VR sessions per week for up to six weeks, with a maximum of 18 regular sessions. Sessions will be delivered by appropriately trained and delegated staff in inpatient geriatric psychiatry units, with research-team oversight. Participants will continue to receive standard inpatient clinical care throughout study participation.

Primary endpoints

Registered primary outcome measures; 10 primary.

  • Recruitment feasibility and recruitment rate From start of recruitment through completion of enrollment, anticipated up to approximately 14 months

    Recruitment flow will be summarized using the numbers and proportions of potentially eligible individuals identified or referred, proceeding to informed consent, meeting formal eligibility criteria, and enrolling. Recruitment rate will be calculated as the number of formally eligible individuals enrolled divided by the total number of formally eligible individuals.

  • Participant retention rate From enrollment through the planned end-of-study timepoint, up to approximately 7 weeks per participant

    Participant retention rate will be calculated as the proportion of enrolled participants who remain in study follow-up through the planned end-of-study timepoint, whether or not they complete all planned regular VR sessions. Completion of an end-of-study or early-termination assessment will be measured separately.

  • Intervention initiation rate From enrollment through the first regular VR intervention session or determination of non-initiation, anticipated within approximately 2 weeks per participant

    Intervention initiation rate will be calculated as the proportion of enrolled participants who initiate at least one regular VR intervention session. Familiarization or orientation will not constitute intervention initiation.

  • Intervention adherence and session completion During the VR intervention period, up to approximately 6 weeks

    Intervention adherence will be calculated among participants who initiate at least one regular VR intervention session as the number of participant-specific planned regular VR sessions completed as tolerated divided by the total number of participant-specific planned regular VR sessions. Participants may have up to 18 planned regular VR sessions over up to six weeks. Familiarization will be excluded from the adherence calculation.

  • Session-delivery feasibility During the VR intervention period, up to approximately 6 weeks

    Prospectively planned regular VR sessions that are offered but not initiated, stopped early, deferred, or not conducted will be summarized by frequency and reason. Reasons may include participant refusal or unavailability, clinical or safety considerations, discharge or transfer, medication-related timing, staffing or workflow limitations, infection-prevention requirements, or device and technical problems.

+5 more primary endpoints

Lead sponsor's other trials

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, most recent start first.

Similar trials

Same condition (Psychomotor Agitation) and phase, most recent start first.